HUE056142T2 - Szubsztituált nitrogéntartalmú vegyületek - Google Patents

Szubsztituált nitrogéntartalmú vegyületek

Info

Publication number
HUE056142T2
HUE056142T2 HUE18733083A HUE18733083A HUE056142T2 HU E056142 T2 HUE056142 T2 HU E056142T2 HU E18733083 A HUE18733083 A HU E18733083A HU E18733083 A HUE18733083 A HU E18733083A HU E056142 T2 HUE056142 T2 HU E056142T2
Authority
HU
Hungary
Prior art keywords
containing compounds
nitrogen containing
substituted nitrogen
substituted
compounds
Prior art date
Application number
HUE18733083A
Other languages
English (en)
Hungarian (hu)
Inventor
Navnath Dnyanoba Yadav
Rajeev S Bhide
Rajesh Onkardas Bora
Prashantha Gunaga
Manoranjan Panda
Eldon Scott Priestley
Jeremy Richter
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUE056142T2 publication Critical patent/HUE056142T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE18733083A 2017-06-01 2018-05-31 Szubsztituált nitrogéntartalmú vegyületek HUE056142T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201711019293 2017-06-01
IN201811004486 2018-02-06

Publications (1)

Publication Number Publication Date
HUE056142T2 true HUE056142T2 (hu) 2022-01-28

Family

ID=62685190

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18733083A HUE056142T2 (hu) 2017-06-01 2018-05-31 Szubsztituált nitrogéntartalmú vegyületek

Country Status (27)

Country Link
US (6) US10501449B2 (enExample)
EP (2) EP3630752B1 (enExample)
JP (2) JP7084946B2 (enExample)
KR (1) KR102655318B1 (enExample)
CN (1) CN110678463B (enExample)
AU (1) AU2018275552B2 (enExample)
CA (1) CA3065309A1 (enExample)
CL (1) CL2019003486A1 (enExample)
CO (1) CO2019013589A2 (enExample)
CY (1) CY1124479T1 (enExample)
DK (1) DK3630752T3 (enExample)
ES (2) ES2981919T3 (enExample)
HR (1) HRP20211262T1 (enExample)
HU (1) HUE056142T2 (enExample)
IL (1) IL271036B2 (enExample)
LT (1) LT3630752T (enExample)
MX (1) MX389581B (enExample)
MY (1) MY201325A (enExample)
PE (1) PE20200386A1 (enExample)
PL (1) PL3630752T3 (enExample)
PT (1) PT3630752T (enExample)
RS (1) RS62277B1 (enExample)
SI (1) SI3630752T1 (enExample)
SM (1) SMT202100512T1 (enExample)
TW (1) TWI791527B (enExample)
WO (1) WO2018222795A1 (enExample)
ZA (1) ZA201908488B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018093569A1 (en) 2016-11-03 2018-05-24 Bristol-Myers Squibb Company Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
US10501449B2 (en) * 2017-06-01 2019-12-10 Bristol-Myers Squibb Company Substituted nitrogen containing compounds
CA3165424A1 (en) 2019-12-20 2021-06-24 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
EP4146219A4 (en) * 2020-05-06 2024-05-22 Biohaven Therapeutics Ltd. PROCESS FOR PREPARING VERDIPERSTAT
TW202308619A (zh) 2021-05-04 2023-03-01 美商特納亞治療股份有限公司 用於治療代謝疾病和hfpef的hdac6抑制劑
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用
CN114957222B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 化合物及其制备方法和用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642228B1 (en) 1999-06-24 2003-11-04 Toray Industries, Inc. α1b-adrenergic receptor antagonists
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
JP4399254B2 (ja) 2001-06-20 2010-01-13 キッセイ薬品工業株式会社 含窒素複素環誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体
AU2003223467B2 (en) 2002-04-08 2007-10-04 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2481229C (en) 2002-04-08 2010-09-21 Merck & Co., Inc. Substituted pyrazine inhibitors of akt
KR20070036149A (ko) 2004-07-16 2007-04-02 얀센 파마슈티카 엔.브이. 이량체 피페리딘 유도체
BRPI0516915A (pt) 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
EP2564857B1 (en) 2008-03-06 2017-05-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
KR20120036850A (ko) 2009-05-15 2012-04-18 노파르티스 아게 알도스테론 신타제 억제제로서의 벤족사졸론 유도체
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011103536A1 (en) 2010-02-19 2011-08-25 Arizona Board Of Regents Multifunctional radical quenchers and their use
US20130165440A1 (en) 2010-09-14 2013-06-27 Exelixis, Inc. JAK1 Inhibitors
EP2632465B1 (en) 2010-10-27 2015-12-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012058134A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CA2844310A1 (en) * 2011-08-19 2013-02-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
TW201317213A (zh) 2011-09-16 2013-05-01 Merck Sharp & Dohme 腎外髓質鉀通道抑制劑
EP2771005B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9108947B2 (en) 2011-10-31 2015-08-18 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
EP2773351B1 (en) 2011-10-31 2017-08-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
WO2013090271A1 (en) 2011-12-16 2013-06-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014015495A1 (en) 2012-07-26 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
WO2014085210A1 (en) 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014099633A2 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections
EP2956142B1 (en) 2013-02-18 2017-09-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2968288B1 (en) 2013-03-15 2018-07-04 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015017305A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
PL3055302T3 (pl) 2013-10-11 2019-05-31 Hoffmann La Roche Podstawione związki heterocykliczne sulfonamidowe użyteczne jako modulatory TRPA1
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015090579A1 (en) 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
EP3083573B1 (en) 2013-12-18 2024-08-07 Merck Sharp & Dohme LLC Inhibitors of the renal outer medullary potassium channel
WO2015096035A1 (en) 2013-12-24 2015-07-02 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2015103756A1 (en) 2014-01-09 2015-07-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
RU2017104110A (ru) 2014-07-14 2018-08-15 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
WO2016008064A1 (en) 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2016060941A1 (en) 2014-10-14 2016-04-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065582A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065602A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2016065603A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US20170275292A1 (en) 2014-10-31 2017-09-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016091042A1 (zh) 2014-12-08 2016-06-16 江苏恒瑞医药股份有限公司 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用
CN105693706B (zh) 2014-12-10 2019-11-22 江苏恒瑞医药股份有限公司 异苯并呋喃酮类衍生物、其制备方法及其在医药上的应用
EP3250204B1 (en) 2015-01-29 2019-10-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2017001991A1 (en) 2015-06-29 2017-01-05 Crystalmorphix Technologies Pvt. Ltd Cocrystals of trigonelline
SG11201809173TA (en) 2016-04-20 2018-11-29 Bristol Myers Squibb Co Substituted bicyclic heterocyclic compounds
WO2018093569A1 (en) 2016-11-03 2018-05-24 Bristol-Myers Squibb Company Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors
US10501449B2 (en) 2017-06-01 2019-12-10 Bristol-Myers Squibb Company Substituted nitrogen containing compounds

Also Published As

Publication number Publication date
MX2019014411A (es) 2020-02-05
MX389581B (es) 2025-03-20
US20180346453A1 (en) 2018-12-06
KR20200011986A (ko) 2020-02-04
CL2019003486A1 (es) 2020-05-15
KR102655318B1 (ko) 2024-04-04
CY1124479T1 (el) 2022-07-22
JP2022130404A (ja) 2022-09-06
ES2885243T3 (es) 2021-12-13
JP2020522490A (ja) 2020-07-30
JP7406592B2 (ja) 2023-12-27
PL3630752T3 (pl) 2021-11-02
EP3630752A1 (en) 2020-04-08
TWI791527B (zh) 2023-02-11
EP3630752B1 (en) 2021-06-30
BR112019024950A2 (pt) 2020-06-23
JP7084946B2 (ja) 2022-06-15
IL271036A (en) 2020-01-30
PE20200386A1 (es) 2020-02-24
MY201325A (en) 2024-02-16
SMT202100512T1 (it) 2021-11-12
USRE49700E1 (en) 2023-10-17
EP3929194B1 (en) 2024-04-17
RS62277B1 (sr) 2021-09-30
IL271036B (en) 2022-11-01
WO2018222795A1 (en) 2018-12-06
CN110678463A (zh) 2020-01-10
CO2019013589A2 (es) 2020-04-01
LT3630752T (lt) 2021-08-25
CA3065309A1 (en) 2018-12-06
US10501449B2 (en) 2019-12-10
ZA201908488B (en) 2023-10-25
TW201902888A (zh) 2019-01-16
AU2018275552A1 (en) 2020-01-23
US20200109135A1 (en) 2020-04-09
ES2981919T3 (es) 2024-10-11
IL271036B2 (en) 2023-03-01
EP3929194A1 (en) 2021-12-29
SI3630752T1 (sl) 2021-10-29
CN110678463B (zh) 2023-06-06
AU2018275552B2 (en) 2022-01-20
PT3630752T (pt) 2021-08-10
US20200339550A1 (en) 2020-10-29
US20240327390A1 (en) 2024-10-03
HRP20211262T1 (hr) 2021-11-12
DK3630752T3 (da) 2021-08-09
US20230124468A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
ZA201908488B (en) Substituted nitrogen containing compounds
GB201720187D0 (en) Novel Compounds
IL272562A (en) new compounds
GB201702947D0 (en) Novel compounds
PL3668853T3 (pl) Nowe związki
GB201721729D0 (en) Novel compounds
GB201721732D0 (en) Novel Compounds
GB201721735D0 (en) Novel Compounds
GB201721727D0 (en) Novel compounds
GB201721731D0 (en) Novel compounds
GB201721726D0 (en) Novel compounds
GB201721736D0 (en) Novel Compounds
GB201719720D0 (en) Novel compounds
GB201718565D0 (en) Novel compounds
GB201718564D0 (en) Novel compounds
GB201718563D0 (en) Novel compounds
GB201718561D0 (en) Novel compounds
GB201716131D0 (en) Novel compounds
GB201714699D0 (en) Novel compounds
GB201713076D0 (en) Novel compounds
GB201713085D0 (en) Novel compounds
GB201713083D0 (en) Novel compounds
GB201713082D0 (en) Novel compounds
GB201713079D0 (en) Novel Compounds
GB201711682D0 (en) Novel compounds